Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG: 1349)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,039	1,196	1,289	1,209	1,397	576.8
Short-Term Investments	-	-	30	-	-	-
Cash & Short-Term Investments	1,039	1,196	1,319	1,209	1,397	576.8
Cash Growth	-16.41%	-9.35%	9.13%	-13.46%	142.18%	-1.94%
Accounts Receivable	524.88	620.49	679.12	672.49	583.1	504.6
Other Receivables	3.3	1.34	5.14	1.18	0.91	6.8
Receivables	528.18	621.82	684.26	673.66	584	511.39
Inventory	47.2	43.65	40.53	35.63	36.01	31.87
Other Current Assets	42.86	8.05	25.1	9.77	9.67	18.18
Total Current Assets	1,657	1,869	2,069	1,928	2,027	1,138
Property, Plant & Equipment	499.79	475.33	351.51	301.92	248.77	260.21
Long-Term Investments	280.24	287.53	306.37	327.86	66.71	28.08
Other Intangible Assets	74.32	86.35	62.32	88.46	56.18	60.46
Long-Term Deferred Tax Assets	101.54	100.87	85.9	79.22	62.97	58.18
Long-Term Deferred Charges	6.01	11.32	43.09	36.12	32.53	17.39
Other Long-Term Assets	8.45	45.85	57.62	19.64	6.97	2.27
Total Assets	2,627	2,877	2,976	2,781	2,501	1,565
Accounts Payable	12.87	8.05	7.43	8.17	5.27	6.83
Accrued Expenses	1.65	36.86	34.67	53.78	48.73	320.69
Short-Term Debt	-	-	101	-	-	148.94
Current Portion of Leases	3.01	6.33	8.22	8.68	6.09	4.03
Current Income Taxes Payable	1.37	1.61	1.63	10.4	4.6	18.65
Current Unearned Revenue	0.37	334.45	412.77	348.87	297.01	2.04
Other Current Liabilities	246.54	117.72	107.63	98.3	66.22	70.17
Total Current Liabilities	265.8	505.02	673.34	528.2	427.93	571.35
Long-Term Leases	8.29	10.95	15.6	22.59	13.6	2.12
Long-Term Unearned Revenue	0.41	2.15	34.04	40.8	50.69	58.21
Total Liabilities	274.5	518.12	722.99	591.58	492.21	631.68
Common Stock	103.66	103.66	102.9	104.3	104.3	92.3
Additional Paid-In Capital	1,291	1,289	1,225	1,265	1,200	237.8
Retained Earnings	963.64	970.46	934.39	868.43	707.28	615.38
Treasury Stock	-	-	-	-40.82	-	-
Comprehensive Income & Other	-6.08	-5.86	-5.2	-4.05	-0.77	-13.95
Total Common Equity	2,352	2,358	2,257	2,193	2,011	931.53
Minority Interest	0.71	1.01	-4.08	-3.36	-2.44	1.62
Shareholders' Equity	2,353	2,359	2,253	2,190	2,008	933.15
Total Liabilities & Equity	2,627	2,877	2,976	2,781	2,501	1,565
Total Debt	11.29	17.28	124.81	31.26	19.69	155.1
Net Cash (Debt)	1,027	1,179	1,194	1,178	1,377	421.7
Net Cash Growth	-8.72%	-1.33%	1.43%	-14.49%	226.58%	-3.77%
Net Cash Per Share	0.94	1.14	1.16	1.13	1.39	0.46
Filing Date Shares Outstanding	1,037	1,037	1,029	1,032	1,043	923
Total Common Shares Outstanding	1,037	1,037	1,029	1,032	1,043	923
Working Capital	1,391	1,364	1,396	1,400	1,599	566.89
Book Value Per Share	2.27	2.27	2.19	2.12	1.93	1.01
Tangible Book Value	2,278	2,271	2,195	2,104	1,955	871.07
Tangible Book Value Per Share	2.20	2.19	2.13	2.04	1.87	0.94
Buildings	-	199.22	198.52	198.52	197.33	204.68
Machinery	-	388.63	341.74	322.86	292.69	277.42
Construction In Progress	-	229.96	122.37	48.9	1.83	0.33

Source: S&P Capital IQ. Standard template. Financial Sources.